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Abstract 
A simple, precise, rapid and accurate RP- HPLC method was developed for the Estimation of Pazopanib HCl 
(PZP) in tablet dosage forms. An XTerra RP C18, (250X4.6 with 5 microns particle size) and the mobile phase, 
consisting of 0.03M KH2PO4 in water adjusting the pH-3.2 with O-Phosphoric Acid: Acetonitrile in ratio of 70:30 
v/v & water: Acetonitrile (50:50 v/v) was used as diluent in the gradient mode. The flow rate was 1.0 ml/min and 
the effluents were monitored at 267 nm. The retention time was 7.392 for Pazopanib HCl. The detector response 
was linear in the concentration of 20-240 µg/mL for PZP. The respective linear regression equation being Y 
(528142.1276 = 172694.049x + 428066.7611 for PZP. The Limit of Detection (LOD) is 0.10 & The Limit of 
Quantification (LOQ) is 0.30 for PZP respectively. The % assay of PZP was found out to be 99.49%. The method 
was validated by determining its accuracy, precision and system suitability. The results of the study showed that 
the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine 
determination of PZP in bulk drug and in its pharmaceutical dosage forms. 
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1. Introduction 
Pazopanib HCl (PZP) chemically, 5-[[4-[(2, 3-
dimethyl-2H-indazol-6- yl) methylamino]-2-
pyrimidinyl] amino]- 2-methylbenzenesulfonamide 
monohydrochloride. (Figure: 1).The empirical 
formula is C21H23N7O2S•HCl & the molecular weight 
is 473.99 gms/mol. It  is a potent and selective multi-
targeted receptor tyrosine kinase inhibitor of VEGFR-
1, VEGFR-2, VEGFR-3,PDGFR-a/β1, and c-kit that 
blocks tumor growth and inhibits angiogenesis2. It has 
been approved for renal cell carcinoma and soft tissue 
sarcoma3-5 and also active in ovarian 
cancer6. Pazopanib also appears effective in the 
treatment of non-small cell lung carcinoma. Literature 
survey reveals a few chromatographic methods7, 8 to 
determine PZP in tablet dosage form and also in 
biological fluids.   HPLC methods are useful in the 
determination of drugs in pharmaceutical 
formulations, especially those containing more than 
one active component. From the literature, neither 
liquid chromatography methods nor assay methods 
have been reported for the estimation of PZP in 
pharmaceutical dosage forms. The availability of an 
HPLC method with high sensitivity and selectivity 
will be very useful for the determination of PZP in 
pharmaceutical formulations. The aim of the study 
was to develop a simple, precise and accurate reverse-
phase HPLC method for the estimation of PZP in bulk 
drug samples and also in pharmaceutical dosage 
forms.   
 
Pazopanib HCl ((Figure: 1) 
                                                                                                
2. Experimental: 
2.1 Materials/Chemicals and Reagents:  Pazopanib 
HCl was obtained as a gift sample from M/s 
GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx 
India), Mumbai. Acetonitrile, Methanol and water 
used were of HPLC grade (Qualigens). Potassium 
Dihydrogen Orthophosphate and Ortho- Phosphoric 
Acid were obtained from SDFCL, Mumbai. 
Commercially available tablets (Votrient®- GSK Rx 
India) were procured from local market. 
2.2 Chromatography Instrument: Quantitative HPLC 
was performed on liquid Chromatograph, Waters 
separation 2996, PDA detector module equipped with 
automatic injector with injection volume 10 µl, and 
2693 pump. An XTerra, RP-C18 Column (250x4.6 
mm i.d; particle size 5 µ) was used. The HPLC system 
was equipped with Empower 2 Software.  The column 
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was maintained at 40o C and eluted under isocratic 
conditions over 20.0 min at a flow rate of 1.0 ml/min. 
2.3 HPLC Conditions:  The contents of the Mobile 
Phase - consisting of 0.03M KH2PO4 in water 
adjusting the pH: 3.2 with O-Phosphoric Acid: 
Acetonitrile in ratio of 70:30 v/v & water: Acetonitrile 
in ratio of 50:50 v/v was used as diluent in the 
gradient mode. They were filtered before use, through 
a 0.45 µm membrane filter, and pumped from the 
respective solvent reservoirs to the column at a flow 
rate of 1.0 ml/min. The run time was set at 20.0 min 
and the column temperature was ambient. Prior to the 
injection (20 µl) of the drug solution, the column was 
equilibrated for at least 30 min with the mobile phases 
flowing through the system. The eluents were 
monitored at 267 nm. 
2.4 Preparation of the Primary Standard/Stock Drug 
Solution: A standard stock solution of the drug was 
prepared by dissolving 100 mg of PZP in 50 ml 
volumetric flask containing 15 ml of diluent (Water: 
Acetonitrile in ratio of 50:50 v/v), sonicated for about 
15 min and then made up to 50 ml with Methanol to 
get standard stock solution of 0.2 mg/mL of PZP. 
2.5 Preparation of the Working Standard Drug 
Solution: 5ml of the above stock solution was taken 
in 50 ml volumetric flask and made up to 50 ml with  
diluent (Water: Acetonitrile in ratio of 50:50 v/v) to 
get a concentration of 200 µg/mL of PZP respectively. 
2.6 Preparation of Sample solution: Twenty tablets 
(Votrient®- GSK Rx India) were weighed, and then 
powdered. A sample of the powdered tablets, 
equivalent to mixture containing concentration of 
each 0.2 mg/mL of PZP active ingredients, was mixed 
with 15 ml of Water: Acetonitrile in ratio of 50:50 v/v 
as diluent in 50 ml volumetric flask. The mixture was 
allowed to stand for 1 hr with intermittent sonication 
to ensure complete solubility of the drug, and then 
filtered through a 0.45 µm membrane filter, followed 
by adding Methanol up to 50 ml to obtain a stock 
solution. 5ml of the above sample stock solution was 
taken in 50 ml volumetric flask and made up to 50 ml 
with diluent to get a concentration of 200 µg/mL of 
PZP. 
2.7 Linearity: Aliquots of standard PZP stock solution 
was taken in different 10 ml volumetric flasks and 
diluted up to the mark with the mobile phase such that 
the final concentrations of PZP was in the range of 
10-300 µg/mL. Each of these drug solutions (20 µL) 
was injected three times into the column, and the peak 
areas and retention times were recorded. Evaluation 
was performed with PDA detector at 267 nm and the 
Calibration graph was obtained by plotting peak area 
versus concentration in µg/mL of PZP (Figure: 2). 
The plot of peak areas of each sample against 
respective concentration of PZP was found to be 
linear in the range of 20-240 µg/mL with correlation 
coefficient of 0.998. Linear regression least square fit 
data obtained from the measurements are given in 
Table I. The respective linear regression equation 
being Y= 528142.1276x + 428066.7611 for PZP. The 
regression characteristics, such as slope, intercept, and 
% RSD were calculated for this method and given in 
Table I. 
2.8 Accuracy: Accuracy was evaluated in triplicate by 
addition of three different amounts of PZP, to a 
previously analyzed sample and comparing the 
amounts of analytes recovered with the amounts 
added. The amounts added were equivalent to 80, 
100, and 120% of the amount originally present. 
%Recovery and RSD (%) were calculated for amount 
added. From the data obtained, it is obvious that the 
method is remarkably accurate, which ensures that 
this method produces reliable results as depicted in 
Table: II. 
2.9 Precision: The precision of the method was 
ascertained, separately from the peak area obtained by 
actual determination of six replicas of a fixed amount 
of the drug and formulation.  
The HPLC system was set up, describing 
chromatographic conditions, mentioned as above and 
following the system equilibration of the working 
standard solution containing 200 µg/mL of PZP, by 
injecting six times and recording the response peak 
areas. The precision was repeated with the formulated 
sample for the same concentrations by injecting the 
working sample solutions containing 200 µg/mL of 
PZP. The sample (Votrient®- GSK Rx India), was 
processed six times for the response of peak area. The 
% Relative Standard Deviation (RSD) and % range of 
error (at 0.05 and 0.01 confidence levels) were 
calculated and presented in Tables: III & IV 
respectively.  
2.10 Limits of Detection and Quantitation: Limit of 
Detection (LOD) of the method was determined as the 
lowest concentrations of active pharmaceutical 
ingredients producing a signal-to-noise (S/N) ratio of 
about 3. The Limit of Quantitation (LOQ) was 
determined as the lowest concentrations of active 
pharmaceutical ingredients capable of being 
quantified with acceptable accuracy and precision 
producing signal-to-noise (S/N) ratio of about 10.  
2.11 Method Applicability: The present developed 
method was evaluated by applying to Pharmaceutical 
dosage forms for the estimation of PZP by our 
research group. 
2.11.1 Assay: 20 µl of sample solution (Votrient®- 
GSK Rx India) was injected into the injector of liquid 
chromatography. The retention time was found to be 
7.386 min for PZP. The amount of drug present per 
tablet was calculated by comparing the peak area of 
the sample solution with that of the standard solution. 
The data are presented in Table II. 
2.11.2 Recovery Studies: Accuracy was determined 
by recovery studies of PZP; known amount of 
standard was added to the pre-analyzed sample and 
subjected to the proposed HPLC analysis. Results of 
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recovery studies are shown in Table II. The study 
was done at three different concentration levels. 
 
3. Results and Discussion 
 
3.1 HPLC Method Development and Optimization9: 
In response to lack of simple, reliable and easy-to-use 
method for the determination of PZP concentrations 
in pharmaceutical matrices, an isocratic RP-HPLC 
method was developed for quantification of above 
mentioned, API. We examined several HPLC method 
variables with respect to their corresponding effects 
on the result of analysis. To optimize the 
chromatographic conditions, different combinations 
of Methanol-Water, Methanol – Acetonitrile, Water – 
Acetonitrile & Ortho- Phosphoric Acid - Acetonitrile 
were tested. Ortho- Phosphoric Acid with Acetonitrile 
(70:30 v/v) was promisingly preferred, because it 
resulted in greater resolution of API after several 
preliminary investigatory runs, compared with other 
mobile phases. The other parameters in this factorial 
design were different column, temperature, variation 
in flow rate, detection wavelength, buffer pH 
variation in mobile phase and volume of injection. 
Buffer molarity was changed and optimum buffer 
strength was selected as 0.03M Potassium 
Dihydrogen Orthophosphate in water adjusted to pH 
3.2, on the basis of theoretical plate number. At 267 
nm, UV responses of all three active pharmaceutical 
analytes were good and free form interferences. Under 
these conditions, the analyte peaks were well defined 
and free from tailing. Considering the whole body of 
the data obtained from this extensive study, the set of 
conditions indicated earlier in this article was selected 
for further validation.  Typical chromatogram (Std & 
Working Sample) of PZP has been shown in Figure: 
5 & 6. 
The system suitability tests were carried out on 
freshly prepared standard stock solutions of PZP. 
Parameters that were studied to evaluate the 
suitability of the system were discussed and presented 
in Table V. 
3.2 Method Validation Tests: Recommended method 
validation characteristics including Method precision 
(RSD, %), Method accuracy (Recovery % and RSD, 
%), Linear range (Correlation Coefficient), and LOD 
& LOQ, were investigated systematically.  
3.3 Linearity:  The plot of peak areas of each sample 
against respective concentrations were found to be 
linear, in the range of 20-240 µg/ml for PZP with 
Correlation Coefficient of 0.998 (Table: 1). Linear 
regression least square fit data obtained from the 
measurements are given in Table: 1. The respective 
linear regression equation being Y= 172694.049x + 
428066.7611 for PZP. The regression characteristics, 
such as slope, intercept, and %RSD were calculated 
for this method and given in Table I. The regression 
characteristics, such as slope, intercept, and %RSD 
were calculated for this method and given in Table: 
1.These results show that there was an excellent 
correlation between peak areas and analyte 
concentration. 
3.4 Accuracy: Recovery of the individual substances 
at 80%, 100%, and 120% of specified concentrations 
were between 92.61% -109.57%, which proves the 
accuracy of the method. From these data, RSD was 
always less than 1%, which indicates it is obvious that 
the method is remarkably accurate, produces reliable 
results (Table: II) 
3.5 Precision: The low value (<1%) of RSD indicates 
the repeatability of the method. These data indicate a 
considerable degree of precision and reproducibility 
for the method both during one analytical run and 
between different runs (Table: III & IV). 
3.6 Robustness:  Robustness was studied out to 
evaluate the effect of small but deliberate variations in 
the chromatographic conditions at three different 
levels, i.e. –2, 0, +2. To determine the robustness of 
this method, the experimental conditions were 
deliberately altered at three different levels and 
retention time and chromatographic response were 
evaluated. One factor at a time was changed to study 
the effect. Variation of the columns with wavelength 
by ±2 nm (263 nm and 267 nm), mobile phase flow 
rate by ±2 mL min−1 (0.8 mL min−1 and 1.2 mL 
min−1), mobile phase pH by ±0.2 units (pH 3.0 and 
3.4) had no significant effect on the retention time and 
chromatographic response of the method, indicating 
that the method was robust. The results are shown in 
Table: VI. 
3.7 Limit of Detection (LOD) and Limit of 
Quantification (LOQ):   The Limit of Detection 
(LOD) found was 0.05% and The Limit of 
Quantification (LOQ) analyzed was 0.15% for PZP. 
These values reflect the high sensitivity of the 
method, which is of great importance in most studies 
and also indicating the method can be used for 
detection and quantification of analytes in a very wide 
concentration range. 
3.8 Specificity:  No evidence of  signals, in the 
corresponding times of the chromatogram were 
monitored as a sign of potential interfering peaks, 
were found when the pharmaceutical formulations 
were tested. Hence, this method can be used reliably 
for the estimation of respected active pharmaceutical 
ingredients in a variety of dosage forms.  
 
4. Conclusion 
A simple and easily available HPLC method was 
developed in this study for the quantification of PZP 
in pharmaceutical matrices. The main advantages of 
this method are its considerably shorter run times, 
easy-to-use and its simplicity. All of these properties 
are very important in practice, particularly when a 
large number of samples are to be analyzed. The 
absence of additional peaks in the chromatogram 
Research Article                                                                                   Khan et al /2013 
  
27 
indicates non-interference of the common excipients 
used in the tablets. The results of validation tests 
were, collectively, indicative for a method with a 
relatively wide linear range, acceptable precision and 
accuracy and practically reliable sensitivity. The 
method enables simple, selective, sensitive, and 
specific analysis of PZP and can be used for routine 
analysis in pharmaceutical quality control within a 
short time. 
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Table I: Linear regression data of calibration 
curves 
 
Parameter Pazopanib HCl 
Concentration range(µg/mL) 20-120 
Slope (m) 172694.049 
Intercept (Y) 528142.1276 
Standard error of estimate (c) 428066.7611 
Correlation coefficient (r) 0.998 
Linear regression (r2) 0.997 
%RSD 0.4 
 
Table II: Assay & recovery Accuracy studies of pazopanib HCl in tablet dosage forms 
 
Tablet formulation 
Amount claim 
(mg/tablet) 
Amount Obtained (mg)* 
by proposed method 
** % Recovery by the 
Proposed method 
Pazopanib HCl Pazopanib HCl Pazopanib HCl 
1) 120% 200 203.27 109.57 
2) 100% 200 200.05 99.26 
3)  80% 200 197.75 92.61 
Average Mean 200 200.35 100.48 
*Average of three determinations                           ** After spiking the sample  
   
Accuracy parameter Pazopanib HCl 
Assay (120%) 129.50% 
Assay (100%) 109.26% 
Assay (80%) 88.22% 
 Standard Spiked 
% RSD (120%) 0.1 0.3 
% RSD (100%) 0.5 0.4 
% RSD (80%) 0.3 0.3 
 Area 
Standard Deviation (120%) 30162.5 70663.3 
Standard Deviation (100%) 77817.5 76612.5 
Standard Deviation (80%) 35393.9 39949.7 
 
Table: III: Precision of Recommended Procedure Using API- {Pazopanib HCl} (PZP) & its Formulation 
Matrice (Votrient®) 
 
Sr. No Inj. No 
Name of the 
Standard 
Drug & Conc. 
(200 µg/mL) 
Retention 
time in 
minutes 
Peak 
 Area 
 
Name of the 
Sample Drug 
& Conc. 
 (200 µg/mL) 
Retention 
time in 
minutes 
Peak Area 
 
API (PZP) Formulation Matrice (Votrient®) 
1 1 PZP 7.417 16963518 Votrient® 7.141 16944572 
2 2 PZP 7.358 16939480 Votrient® 7.212 17043405 
3 3 PZP 7.281 16941492 Votrient® 7.210 17076312 
4 4 PZP 7.136 16932832 Votrient® 7.177 16991681 
5 5 PZP 7.199 16894390 Votrient® 7.232 16964333 
6 6 PZP 7.142 16930451 Votrient® 7.148 16956173 
7 Mean 7.255 16933693.8 Votrient® 7.187 16996079.4 
8 Standard Deviation 0.116 22538.3  0.037 52819.9 
9 % RSD 1.60 0.1  0.52 0.3 
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Table IV:  Validation Summary / System Suitability 
Parameter Pazopanib HCl (PZP) (Standard API drug) 
Votrient® 
(Sample drug) 
Theoretical Plates(N) 4036.35 4140.83 
Tailing factor 1.29 1.32 
Retention time(min) 7.392 7.386 
Resolution 2.55 9.40 
Area 17081048 17134315 
% Peak Area 99.93 99.93 
LOD (µg/mL) 0.05 0.05 
LOQ (µg/mL) 0.15 0.15 
 
Table V: Results from testing of the Robustness of the method (n=3, 100% of the Working Standard 
Solution & Sample Solution contains: 200 µg/mL of Pazopanib HCl (PZP) 
Condition 
Studied in 
Robustness 
Modification 
In OFAT 
analysis 
Parameter 
Fixation 
Mean Peak Area 
± S.D 
% RSD 
( Peak Area) 
Mean Retention 
Time (in min) 
± S.D 
% RSD 
(Retention 
time) 
PZP PZP PZP PZP 
Column(s) 
(XTerra 
RP18) 
Hypersil, & 
Inertsil ODS 
C18 3V 
Std 16938497.0 ± 13566.3 0.1 7.155 ± 0.051 0.71 
Sample 16949840.7 ± 35836.6 0.2 7.153 ± 0.073 1.03 
Flow rate  
(1.0 ml/min) 
1.2 ml/min & 
0.8 ml/min 
Std – 
Increase 15839219.6 ± 58320.2 0.4 6.724 ± 0.033 0.49 
Std- 
Decrease 18966766.3 ± 41198.5 0.2 7.865 ± 0.031 0.40 
Sample- 
Increase 16107848.3 ± 77066.4 0.5 6.663 ± 0.026 0.40 
Sample-
Decrease 18890994.4 ± 70374.5 0.4 7.888 ± 0.024 0.31 
pH 
(3.2) 3.4 & 3.0 
Std - 
Increase 17085698.7 ± 59123.4 0.3 7.691 ± 0.009 0.11 
Std- 
Decrease 17084204.4 ± 52304.9 0.3 7.072 ± 0.013 0.18 
Sample - 
Increase 17055489.3 ± 58283.0 0.3 7.677 ±  0.011 0.15 
Sample - 
Decrease 17053343.7 ± 50867.4 0.3 6.946 ± 0.037 0.53 
Figure 4: Calibration Curve of the Pazopanib HCl (PZP) by RP-HPLC 
 
Figure 5 & 6:  Typical Chromatogram of Pazopanib HCl (Standard and Working Sample) by RP-HPLC 
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